The Influence of Vitamin D Metabolism on Gene Expression, Matrix Production and Mineralization During Osteoprecursor Cell-Based Bone Development by Mason, Shelley S. et al.
Portland State University
PDXScholar
Biology Faculty Publications and Presentations Biology
4-2014
The Influence of Vitamin D Metabolism on Gene Expression,







Oregon Health & Science University
Randy D. Zelick
Portland State University
Let us know how access to this document benefits you.
Follow this and additional works at: http://pdxscholar.library.pdx.edu/bio_fac
Part of the Medical Biochemistry Commons, Oral Biology and Oral Pathology Commons, and
the Prosthodontics and Prosthodontology Commons
This Article is brought to you for free and open access. It has been accepted for inclusion in Biology Faculty Publications and Presentations by an
authorized administrator of PDXScholar. For more information, please contact pdxscholar@pdx.edu.
Citation Details
Mason, S, Kohles S, Winn, S, Zelick R. The Influence of Vitamin D Metabolism on Gene Expression, Matrix Production and
Mineralization During Osteoprecursor Cell-Based Bone Development. J Endocrinol Metab. 2014;4(1-2):1-12
Original Article J Endocrinol Metab. 2014;4(1-2):1-12
PressElmer 
Articles © The authors   |   Journal compilation © J Endocrinol Metab and Elmer Press Inc™   |   www.jofem.org
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited
The Influence of Vitamin D Metabolism on Gene Expression, 
Matrix Production and Mineralization During 
Osteoprecursor Cell-Based Bone Development
Shelley S. Masona, b, Sean S. Kohlesa, c, e, Shelley R. Winnc, d, Randy D. Zelicka
Abstract
Background: Multipotential precursor cell lines derived from hu-
man bone marrow, capable of differentiating into cartilage or bone, 
may provide a useful tissue development model for studying the 
regulation and metabolism of putative growth and differentiation 
factors necessary for tissue regeneration. In mammals, the process 
of bone development depends on the proliferation and differentia-
tion of osteoblast lineage cells, and the subsequent synthesis and 
mineralization of bone extracellular matrix (ECM). Vitamin D me-
tabolites play a pivotal role in bone and mineral homeostasis, and 
are positive factors on bone development. Recently, it was dem-
onstrated that a human-derived engineered osteoblast precursor 
cell line (OPC1), derived from human bone marrow, can metabo-
lize the parental precursor vitamin D3 (vitaD3) to the active steroid 
1α,25-dihydroxyvitamin D3 (1,25OH2D3), and elicit an osteogenic 
response that results in the decrease in proliferation and increase 
in ECM synthesis during early bone development. The aim in this 
study is to characterize gene expression, matrix production and 
mineralization within a bone development model.
Methods: We investigated whether vitaD3 influences bone ECM 
mineralization in the same manner as 1,25OH
2
D3 in confluent cul-
tures of OPC1s. In addition, we explored the influence of vitamin D 
metabolites, in combination with other commonly used osteogenic 
factors, ascorbic acid, β-glycerophosphate, dexamethasone (dex) 
and recombinant human bone morphogenetic protein-2 (rhBMP-2) 
on the osteoinduction of OPC1.
Results: It was demonstrated that OPC1 expresses the mRNA for 
the enzymatic equipment necessary to convert vitaD3 to 1,25OH2D3, 
as well as the mRNA expression of the catabolic enzyme known 
to regulate the concentration of active 1,25OH
2
D3. It was also 
demonstrated that mRNA expression for the vitamin D receptor 
(VDR) was influenced by both vitaD3 and 1,25OH2D3. Differential 
results using vitamin D metabolites in combination with ascorbic 
acid, β-glycerophosphate, dex and/or rhBMP-2 were observed in 
alkaline phosphatase (ALP) activity and calcium deposition, and 
mRNA expression of procollagen type I (proColI), osteocalcin 
(OC) and osteopontin (OP).
Conclusions: Overall it was demonstrated that vitamin D in combi-
nation with osteogenic factors influences the temporal bone devel-
opment sequence in a positive manner.
Keywords: Cell and tissue engineering; Osteoinduction; Osteogen-
ic factors; Stem cells; Mesenchymal stromal cells; Cholecalciferol; 
Calcitriol
Introduction
Most of the load-bearing demand placed on the human body 
is transduced by skeletal tissue, and the skeleton’s capacity 
to articulate is essential for mobility and locomotion [1]. 
Consequently, cartilage and bone defects due to trauma, dis-
ease and developmental abnormalities may result in severe 
disabling pain and immobility for millions of people world-
wide [2]. Multipotential precursor cell lines derived from hu-
man bone marrow, capable of differentiating into cartilage 
or bone, may provide a useful tissue development model for 
studying the regulation and metabolism of putative growth 
and differentiation factors necessary for tissue regeneration.
There are several factors that need to be taken into con-
sideration for in vitro model systems, such as cell source and 
acquisition, phenotypic stability, reproducibility and the in-
corporation of appropriate signaling molecules. One of the 
challenges in using mesenchymal stromal cells (MSCs), 
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or progenitor cells isolated from bone marrow aspirates, is 
isolation sufficiency and expansion. This is due to the rela-
tively low frequency at which these cells exist in the mar-
row stroma (reported to be in the range of 1/10,000 cells to 
1/100,000 cells) [1, 3, 4]. In addition, MSCs have a finite 
capacity for self-renewal, and the potential to proliferate and 
differentiate diminishes with age. MSC isolates also tend to 
be heterogeneous, containing progenitor cells with varying 
levels of potency. By contrast, the osteoblastic precursor cell 
line (OPC1) is a conditionally immortalized cell line derived 
from human bone, and has been demonstrated to maintain 
phenotypic stability and a consistent pattern of differentia-
tion for more than 70 passages, providing an ideal model for 
the study of osteoblast differentiation and bone development 
as an alternative to MSCs [5]. We have used the OPC1 in a 
previous study and have shown it to provide a consistent and 
reproducible culture system for evaluating bone development 
[6]. We were able to demonstrate the extra-endocrine me-
tabolism of vitamin D3 (vitaD3) to 1α,25-dihydroxyvitamin 
D3 (1,25OH2D3) by OPC1, which resulted in decreased pro-
liferation and increased alkaline phosphatase (ALP) activity 
and calcium deposition associated with extracellular matrix 
(ECM) bone maturation and mineralization.
In the early 1900s, vitamin D was the fourth identified 
essential vitamin, thus named vitamin “D” by convention. It 
was not until 50 years later that it was realized that vitamin D 
is metabolized and acts as a steroid hormone in an endocrine 
manner, a paradigm that has dominated the classic thought 
of vitamin D function until the end of the 20th century [7]. 
Recently, it has been demonstrated that a number of organ 
systems are influenced by vitamin D in an autocrine man-
ner, that is, 1,25OH
2
D3 is being synthesized within those 
cells, and/or within adjacent cells (paracrine action). While 
the vitamin D endocrine system plays a principal role in the 
maintenance of calcium and phosphate homeostasis, extra-
endocrine metabolism has been postulated to have cellular 
functions that include the regulation of proliferation, differ-
entiation and apoptosis in many target tissues [8-11], includ-
ing bone and cartilage.
VitaD3 is biologically inactive in physiologic concentra-
tions until it is sequentially hydroxylated and the polarity is 
increased. VitaD3 is activated by two-sequential hydroxyl-
ations, first by the cytochrome P450 oxidase (CYP) 25-hy-
droxylase, CYP27A1 (mitochondrial) and CYP2R1 (micro-
somal), resulting in the metabolite 25-hydroxyvitamin D3 
(25OHD3), and then to the active metabolite, 1,25OH2D3, by 




D3 is the most active form of vitamin D because 
of its high affinity for the intranuclear vitamin D receptor 
(VDR), mediating its biological influence upon binding. 
VDR belongs to the nuclear hormone receptor family and 
serves as a ligand-dependent transcription factor (TF) that 
controls the expression of vitamin D associated target genes 
which include those associated with calcium homeostasis, 
cellular proliferation and differentiation, cell division and 
cycle arrest, and apoptosis [15-19]. Upon 1,25OH2D3 bind-
ing, VDR forms a heterodimer with the retinoid X recep-
tor, which allows it to bind to vitamin D receptor elements 
(VDREs) in the promoter regions of target genes [8, 14, 17, 
20]. Coupled with other TFs, this complex induces transcrip-
tion of vitamin D responsive genes including those associ-
ated with the CYP-related enzymes required for vitamin D 
metabolism [14, 17, 20-22].
The action of vitamin D is limited by the catabolic en-
zyme 24-hydroxylase (CYP24A1), which results in a com-
pound that is more soluble and has a substantially lower 
affinity for VDR [12, 14, 23]. CYP24A1 has been shown 
to hydroxylate both 25OHD3 and 1,25OH2D3 to form 
24,25OH
2
D3 and 1,24,25OH3D3, respectively [17]. The main 
function of CYP24A1 is to regulate the circulating concen-
tration of 1,25OH
2
D3 by inactivating it. The catabolic path-
way of CYP24A1, collectively known as the C-24 oxida-
tion pathway, starts with the 24-hydroxylation of 25OH
2
D3 
Primer set Forward Reverse
CYP24A1 5’ - GCA GCC TAG TGC AGA TTT - 3’ 5’ - ATT CAC CCA GAA CTG TTG - 3’
CYP27A1 5’ - GGC AAG TAC CCA GTA CGG - 3’ 5’ - AGC AAA TAG CTT CCA AGG - 3’
CYP27B1 5’ - TgT TTg CAT TTg CTC AgA - 3’ 5’ - CCG GGA GAG CTC ATA CAG - 3’
VDR 5’ - CCA GTT CGT GTG AAT GAT GG - 3’ 5’ - GTC GTC GGT GAA GGA - 3’
OC/BGLAP 5’ - CTG GCC ACT GCA TTC TGC - 3’ 5’ - AAC GGT GGT GCC ATA GAT GCG - 3’
OP/SPP1 5’ - AAA TAC CCA GAT GTG GC - 3’ 5’ - AAC CAC ACT ACC TCG GC - 3’
Pro-ColI 5’ - TGA CGA GAC CAA GAA CTG - 3’ 5’ - CCA AAG TCA CCA AAC CTA CC - 3’
Table 1. Oligionucleotide Single-Stranded Molecular Primers Used in Quantitative, Real-Time RT-PCR
      1                                     2
J Endocrinol Metab. 2014;4(1-2):1-12   Vitamin D Metabolism and Bone Development
Articles © The authors   |   Journal compilation ©  J Endocrinol Metab and Elmer Press Inc™   |   www.jofem.org
Figure 1. Temporal alkaline phosphatase activity of OPC1 treated with (A) ethanol vehicle control in standard bone me-
dium (BM-), BM- containing vitamin D3 (BM- vitaD3+) and BM- with 1,25OH2D3 (BM- 1,25OH2D3+); (B) ethanol control 
in osteogenic medium (BM+) containing ascorbic acid, β-glycerophosphate and dexamethasone, BM+ containing vitamin 
D3 (BM+ vitaD3+), and BM+ with 1,25OH2D3 (BM+ vitaD3+); (C) ethanol control in BM+ containing rhBMP (BMP+), BMP+ 
containing vitamin D3 (BMP+ vitaD3+), and BMP+ with 1,25OH2D3 (BMP+ vitaD3+). Cellular isolates were collected on day 
7, 14 and 21 during the differentiation time course. Treatment with both vitamin D metabolites significantly influenced OPC1 
ALP activity in all medium groups (P < 0.01). 
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or 1,25OH
2
D3 followed by sequential steps of hydroxylation 
that lead to the progressive loss of biological activity until 
vitamin D is converted to the water-soluble biliary excretory 
form, calcitroic acid [10, 12, 24]. 1,25OH
2
D3 induces and 
mediates CYP24A1 via an autocatalytic loop through VDRE 
located in the promoter region of the CYP24A1 gene [21]. 
Generally, basal expression of CYP24A1 is extremely low 
but the gene is highly induced by 1,25OH
2
D3 [11, 20]. Thus, 
the synthesis and degradation of 1,25OH
2
D3 is highly regu-
lated, and the concentration is controlled at the cellular level.
Vitamin D affects many aspects of bone cell biology, 
and has been implicated in the regulation of both osteo-
blastic and osteoclastic activity influencing both resorptive 
and synthetic phases of bone remodeling [11]. In addition, 
1,25OH
2
D3 has been demonstrated to regulate osteoblast and 
chondrocyte gene transcription, proliferation, differentiation 
and ECM maturation [11, 25]. VDR is nearly ubiquitously 
expressed, as almost all cells respond to 1,25OH
2
D3 [26], 
and it is known to regulate the function of more than 200 
genes [13, 17-19].
In this study, our objective was to quantify the differenti-
ation of the OPC1 as an osteoprogenitor along the osteoblas-
tic lineage including the events associated with bone devel-
opment in the presence of vitamin D metabolites, vitaD3 and 
1,25OH
2
D3. Additional osteogenic factors included ascorbic 
acid, β-glycerophosphate, dexamethasone and bone morpho-
genetic protein-2 (BMP-2). Because in vitro temporal bone 
development encompasses three stages (proliferation, bone 
ECM maturation and mineralization) and vitamin D has been 
shown to significantly hamper OPC1 proliferation [6], con-
fluent cultures were used in order to investigate the influence 
on bone ECM maturation and mineralization.
 
Materials and Methods
Vitamin D and OPC1 cell cultures
VitaD3 (cholecalciferol) and 1,25OH2D3 (calcitriol) were 
purchased (Sigma-Aldrich, St. Louis, MO), and maintained 
in 10 mM and 10 μM stock solutions in ethanol, respectively. 
All other reagents and chemicals were purchased from the 
Figure 2. (A) Calcium deposition stained with alizarin red stain (ARS) of OPC1 cultured in BM- and either vitamin D metabolites, 
vitamin D3 or 1,25OH2D3. (B) After microscopic analysis, ARS was extracted from each culture well, and quantified on a microplate 
reader. By week three of culture, there was a statistically larger amount of calcium deposition detected by ARS in cells treated with 
either vitamin D3 or 1,25OH2D3 compared to that of the ethanol control (***P < 0.001).
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same vendor unless otherwise indicated. Original OPC1 and 
rhBMP-2 were prepared and maintained locally [5].
Cells were cultured at populations of 2.5 × 105 in 75 
cm2 tissue culture flasks in alpha modified essential medium 
(α-MEM) with 5% fetal bovine serum (FBS). Once conflu-
ent, OPCs were plated in 12-well plates after trypsin-ethyl-
enediaminetetraacetic acid (EDTA) enzymatic removal and 
counted with 0.4% trypan blue (1:1) on a hemacytometer. 
Cultures were then prepared in duplicate at a seeding density 
of 3.0 × 104 cells/well in the initial bone medium (designated 
as BM-) with 200 mM L-glutamine and antibiotics until 85-
90% confluent prior to adding experimental medium. Nine 
variations of medium were utilized in quadruplicates. BM- 
with 95% ethanol (EtOH), in an amount that facilitated the 
EtOH as a vehicle for vitamin D metabolite delivery, pro-
vided a negative control (group 1). The additional groups 
included: BM- supplemented with 1 μM vitaD3 (group 2); 
BM- supplemented with 10 nM 1,25OH
2
D3 (group 3); BM- 
supplemented with osteogenic factors (BM+) comprised of 
50 μg/mL ascorbic acid, 10 mM β-glycerophosphate, 10 nM 
dexamethasone (dex) and 50 μg/mL of ascorbic acid phos-
phate (Wako Chemical, Osaka, Japan), provided as a posi-
tive control (group 4); BM+ supplemented with 1 μM vitaD3 
(group 5); and BM+ supplemented with 10 nM 1,25OH
2
D3 
(group 6). Enhanced supplementation groups were also pre-
pared: BM+ supplemented with rhBMP-2 (BMP+) (group 
7); BMP+ with 1 μM vitaD3 (group 8); and BMP+ supple-
mented with 10 nM 1,25OH
2
D3 (group 9). Fresh medium 
was added every 1 to 2 days.
Bone matrix maturation
ALP activity was monitored, as it is known to be involved 
with ECM maturation and mineralization through increased 
phosphate concentration [27]. ALP levels associated with the 
OPC1 response to both vitaD3 and 1,25OH2D3 in BM-, BM+ 
and BMP+ were determined in duplicate at the previously in-
dicated concentrations. ALP was measured every 7 days. At 
the end of the incubation, the cell layers were washed with 
cold DPBS and 500 μL 0.1% triton-X in DPBS, then stored 
at -80 °C until the end of each experimental period. ALP ac-
tivity in the cell lysates was measured using ρ-nitrophenyl 
Figure 3. (A) OPC1 calcium deposition stained with ARS during culture in BM+ and either vitamin D3 or 1,25OH2D3. (B) After 
microscopic analysis, ARS was extracted from each culture well and read on a microplate reader. By week three of culture, there 
again was a larger amount of calcium deposition detected by ARS in cells treated with either vitamin D3 or 1,25OH2D3 compared to 
that of the ethanol control (***P < 0.001). In addition, there was more calcium deposition in the BM+ treatment groups compared 
to all BM- groups (shown in Fig. 2).
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phosphate liquid substrate system at 37 °C for 30 min. Pro-
tein content was measured using a micro-volume spectroph-
ometer system (Epoch; Biotek, Winooski, VT). 
Bone matrix mineralization
Calcium deposition was determined through a histochemical 
analysis of mineralization utilizing Alizarin Red S (ARS). 
ARS staining identified calcium-rich deposits made by the 
cells in culture. This approach is considered a functional in 
vitro endpoint reflecting advanced cell differentiation [28]. 
Every 7 days the cells were fixed in 10% neutral buffered 
formalin for 15 min followed by fixation in 100% cold meth-
anol. Each well was rinsed thoroughly with cold DPBS, and 
stained with 40 mM of ARS (pH = 4.1), at room tempera-
ture for 20 min with gentle shaking. The cell layers were 
rinsed and observed both grossly and microscopically. For 
semi-quantification, ARS was extracted from the cells after 
incubating for 1 h at room temperature in 10% volume to 
volume (v/v) acetic acid with gentle shaking, and then the 
residual dye was further extracted by scraping the cells and 
heating at 85 °C on a heating block with a layer of mineral oil 
to prevent evaporation. The samples were neutralized with 
10% (v/v) ammonium hydroxide and the extracts were read 
at 405 nm on a microplate-reader (Cary 50; Varian Australia 
Pty. Ltd). The samples were compared to a serially diluted 
ARS standard. The resulting data were normalized with total 
protein content measured using a micro-volume spectroph-
ometer system (Epoch; Biotek, Winooski, VT).
Gene sequencing
Quantitative real-time, reverse transcription polymerase 
chain reaction (RT-PCR) analysis techniques were used to 
characterize the activity of the genes associated with vitamin 
D metabolism: CYP24A1, CYP27A1, CYP27B1 and VDR 
[16, 29]. In addition, RT-PCR was used to detect levels of 
osteopontin (OP), procollagen type I (proColI) and osteocal-
Figure 4. (A) OPC1 calcium deposition as stained with ARS during culture in BMP+ containing rhBMP-2 (BMP+) and either vitamin 
D3 or 1,25OH2D3. (B) Quantified ARS as extracted from each culture well and read on a microplate reader. In the second week of 
culture, the BMP+ EtOH control had a larger amount of calcium deposition in comparison with the treatment groups (P < 0.05). By 
week three of culture, there was more calcium deposition detected by ARS in cells treated with either vitamin D metabolites com-
pared to that of the ethanol control (*P < 0.01). In addition, there was a statistically more calcium deposition in the BMP+ treatment 
groups (P < 0.001) compared to all BM- groups (plotted in Fig. 2).
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cin (OC). These noncollagenous and collagenous proteins 
are associated with hydroxyapatite binding and pre-collagen 
synthesis, respectively, during bone development [5]. The 
oligionucleotide RT-PCR primer sequences (Table 1) were 
purchased from a commercial source (Intergrated DNA Tech-
nologies, Coralville, IA). Briefly, messenger ribonucleic acid 
(mRNA) was isolated using 500 μL of a chemical reagent 
(TRIzol, Life Technologies, Grand Island, NY) per well of 
the 12-well plates. Samples were collected every 7 days and 
stored at -80 °C. The mRNA was purified according to the 
reagent manufacturer’s specifications and the concentration 
was determined in units of μg/mL by spectrophotometric 





) (Epoch, Biotek, Winooski, VT). The complemen-
tary deoxyribonucleic acid (cDNA) was synthesized from 2 
μg of the mRNA using a high capacity reverse transcriptase 
kit (Applied Biosystems, Life Technologies) according to 
manufacturer’s instructions. Aliquots of the total cDNA were 
amplified in each PCR using fast green master mix (SYBR, 
Applied Biosystems, Life Technologies) with the acquired 
primers (Table 1). This amplification was performed in a 
quantitative thermocycler (Rotor-gene Q, Qiagen, german-
town, MD) for 45 cycles (30 sec denaturation at 95 °C, 45 
sec annealing at 58 °C and 60 sec extension at 72 °C).
Microscopic imaging
Microscopic images were taken using an advanced transmit-
ted light inverted microscope and accompanying software 
(EVOS-XL and EVOS3, Advanced Microscopy group, 
Bothell, WA). Images were processed using an open source, 
image-processing package (FIJI, ImageJ v1.47d, National 
Institutes of Health, Bethesda, MD). To maintain consisten-
cy, each image was processed in the same manner including 
maintaining consistent light intensities during optical density 
measurements. The operations (Contrast-Limited Adaptive 
Histogram Equalization commands) included background 
subtraction (blocksize 100), mean filter (bin 256) and local 
contrast (maximum slope 2.50).
Statistical analysis
Statistical analyses were carried out using commercial soft-
ware (Prism, Irvine, CA; Excel, Microsoft, Redmond, WA). 
Data were expressed as means ± standard error of the mean 
(SEM) of samples characterized in three 2-week sample sets 
plated in duplicate or quadruplicate, and assayed in dupli-
cate (n = 12 or n = 24, respectively). A two-way analysis of 
co-variance (ANCOVA) with a Bonferonni post-test (direct 
comparison with controls), Dunnett’s test (pairwise com-
parisons) and non-linear regression (polynomial quadratic 
function) were applied to statistically compare the treatment 
groups over time, with asterisks of *P < 0.05, **P < 0.01, and 
***P < 0.001 indicating varying levels of statistical signifi-
cance as noted in the figures. 
Results
Increased ALP activity is known to be associated with os-
teoblast function and the matrix maturation stage of bone 
development. ALP activity here was found to be statistically 
higher (P < 0.01) in groups cultured in standard bone me-
dium (BM-) containing vitaD3 by week two of culture, and 
significantly higher (P < 0.001) in groups containing either 
vitaD3 or 1,25OH2D3 by week three compared to the BM- 
ethanol vehicle control (Fig. 1A). For groups in osteogenic 
medium (BM+) both vitamin D metabolites displayed statis-
tically higher (P < 0.001) ALP activity compared to the BM+ 
EtOH control in both the second and third week (Fig. 1B). 
All groups cultured in BM+ were significantly higher (P < 
0.001) than the groups cultured in BM- during the 3-week 
culture period, and reached maximal ALP, while groups in 
BM- did not reach maximal ALP activity. Groups cultured 
in BM+ containing rhBMP (BMP+) showed a significant in-
crease (P < 0.001) only in the second week compared to the 
BMP+ EtOH control, and by week three all groups displayed 
low levels of ALP activity (Fig. 1C). While groups cultured 
in BM+ continued to increase in ALP activity throughout 
the 3-week culture period, BM+ reached a peak in between 
weeks 1 and 3, and began to decline in between weeks 2 and 
3.
The primary function of osteoblasts is to produce and 
maintain mineralized ECM. For our samples cultured in 
BM- with or without vitamin D metabolites, vitaD3 and 
1,25OH
2
D3, calcium deposition was significantly greater (P < 
0.001) in cultures containing either of the vitamin D metabo-
lites compared with the BM- ethanol control (Fig. 2). OPC1 
cultured in BM+ with or without the vitamin D metabolites 
showed a significantly higher amount of calcium deposition 
(P < 0.001) throughout the 3-week culture period compared 
to that of cultures in BM-. Cultures containing either vitaD3 
or 1,25OH
2
D3 were significantly higher (P < 0.001) than 
the BM+ EtOH control by the third week of culture (Fig. 
3). Cultures containing rhBMP (BMP+) showed a statisti-
cally significant amount of calcium deposition (P < 0.001) 
compared to that of the groups cultured in BM- throughout 
the 3-week culture period. The presence of vitaD3 in BMP+ 
medium caused a larger amount of calcium deposition (P 
< 0.01) compared to that of the BMP+ EtOH control, and 
slightly more deposition (P < 0.05) when in the presence of 
1,25OH
2
D3 (Fig. 4). 
As mentioned, CYP27A1 and CYP27B1 are hydroxy-
lases demonstrated to be involved in the metabolism of 
vitaD3 to 25OHD3, and convert 25OHD3 to 1,25OH2D3, re-
spectively. Here, OPC1 expressed both CYP27A1 (Fig. 5A) 
and CYP27B1 (Fig. 5B) in response to the presence of vi-
taD3, relative to the BM- EtOH control. Increases in both 
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hydroxylases occurred in some of the treatment within the 
first 72 h of treatment (treatment added on day 4 of culture) 
as measured at week one, but decreased dramatically by the 
second week in the continuous presence of vitaD3. In the 
groups containing osteogenic factors (BM+ and BMP+), the 
expression of CYP27A1 was higher then in the BM- group 
treated with vitaD3. However, in groups treated with BMP+, 
CYP27B1 expression was lower then in the BM- and BM+ 
Figure 5. Induced mRNA expression of (A) CYP27A1, (B) CYP27B1, (C) CYP24A1 and (D) VDR in nine treatment group cultures 
of OPC1s including either vitamin D3 or 1,25OH2D3 in standard bone medium (BM-) and medium containing osteogenic factors 
(BM+ and BMP+). Total RNA was isolated and examined by quantitative RT-PCR. Data were normalized by the level of glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH), a protein-coding gene. The figure legend for (A) applies to Fig. 5 and 6 where the 
bars (front to back) are associated with the listed experimental groups (top to bottom).
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groups treated with vitaD3. OPC1 also expressed CYP24A1 
and VDR mRNA in response to vitaD3 and 1,25OH2D3 (Fig. 
5C, D). In the first week, all groups treated with the vitamin 
D metabolites had significant increases (P < 0.001) in both 
CYP24A1 and VDR expression relative to the BM- control. 
BM- cultures treated with vitaD3 expressed a much higher 
amount of CYP24A1 mRNA relative to BM- control, com-
pared to the cultures containing osteogenic factors. After the 
continuous presence of vitaD3, in the second week of culture, 
CYP24A1 expression decreased for the BM- groups, but in-
creased in groups containing BM+ and BMP+. All groups 
treated with vitaD3 and 1,25OH2D3 had statistically more 
VDR mRNA expression (P < 0.001) relative to the BM- con-
trol during the first week of culture, but which decreased by 
the second week.
Synthesis of procollagen type I (proColI) is known to 
precede the production of collagen type I (ColI), a major 
component of bone ECM. This synthesis is enhanced during 
early osteoblast differentiation, while OC and OP are associ-
ated with later stages of osteoblast differentiation and bone 
development. Real-time PCR analysis showed a significant 
increase in proColI mRNA expression (P < 0.001) during 
the first week of OPC1 culture in all groups relative to the 
BM- control, and a higher increase with treatment groups 
containing either vitaD3 or 1,25OH2D3 (Fig. 6A). There was 
no statistically significant expression of proColI mRNA in 
the second week in any of the culture groups (P > 0.05). In 
contrast to the expression of proColI, OP mRNA expression 
was not seen in the first week of culture time in any of the 
groups and increased in both the second and third week of 
culture relative to the BM- control (Fig. 6B). The BMP+ 
control without vitamin D displayed the highest OP mRNA 
expression relative to the BM- control. Similar to OP mRNA 
expression, expression of OC mRNA was highest in the 
BMP+ control group, but was increased in all groups rela-
tive to the BM- control (Fig. 6C). However, in contrast to OP 
mRNA expression, OC mRNA expression was increased in 




In this study, an engineered OPC1 was used to examine 
the effect of vitamin D metabolites, vitaD3 and 1,25OH2D3, 
on the maturation and mineralization of culture-expanded 
cells as a model for bone development. In comparison to 
the untreated cells, vitamin D metabolites in combination 
with ascorbic acid, β-glycerophosphate, dex and/or BMP-
2, produced more calcium deposition and showed a greater 
increase in ALP over time. Cultures containing osteogenic 
factors varied in ALP activity depending on the presence of 
rhBMP-2. In addition to ALP activity and calcium deposi-
tion, mRNA expression of proColI, OC and OP were ana-
lyzed over the 3-week culture period, as well as the mRNA 
expression of genes associated with vitamin D action and 
metabolism.
Osteoblasts are bone-forming cells derived from mul-
tipotential progenitor cells within the bone marrow stroma 
that also are capable of committing to other mesenchymal 
Figure 6. Induced mRNA expression of (A) proColI, (B) OP and (C) OC in nine treatment group OPC1 cultures containing the vitamin 
D metabolites and/or osteogenic factors (see the figure legend for Fig. 5A). Total RNA was isolated and examined by quantitative RT-
PCR and data were again normalized by levels of GAPDH.
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lineages, including fibroblasts, myoblasts, chondrocytes, 
adipocytes and osteoblasts [3, 30]. Once precursors have 
committed to a specific lineage, tissue specific molecules 
are expressed. Phenotypical characteristics of an osteoblast 
include the synthesis and mRNA expression of proColI pre-
ceding ColI, OC, OP, VDR, increased ALP activity and the 
ability to mineralize ECM. When osteoblast precursors com-
mit to the osteoblastic lineage, the osteoblasts express bone 
matrix protein genes at different expression levels depending 
on the maturation level of the cells [31]. For example, imma-
ture mesenchymal cells and preosteoblasts weakly express 
ColI and collagen type II (ColII), while immature osteoblasts 
express OP, and bone sialoprotein (BSP), a component of 
mineralized tissues. Mature osteoblasts meanwhile strong-
ly express OC [31] and may eventually become osteocytes 
when they are embedded into the bone matrix and express 
dentin matrix protein 1 (DMP-1).
In vitro human osteoblasts respond to exogenous 
1,25OH
2
D3 by decreasing their rate of proliferation while 
increasing their expression of mRNA of osteogenic bio-
markers such as OC and OP. While it has been known that 
circulating vitamin D is derived from the kidneys, recently a 
number of studies have demonstrated the extra-renal synthe-
sis of 1,25OH
2
D3 from 25OHD3 in skin, liver, lymph nodes, 
activated monocytes/macrophages, dendritic cells and osteo-
blasts [11]. In contrast to extra-renal metabolism of 25OHD3 
to 1,25OH
2
D3, there have been occasional reports of extra-
hepatic metabolism of vitaD3, but no detailed analysis until 
now. Recently, we demonstrated that OPC1 could metabo-
lize vitaD3 to 1,25OH2D3 in a dose-dependent manner [6], 
and in this present experiment, we were able to demonstrate 
the upregulation of mRNA expression of vitamin D associ-
ated hydroxylases CYP27A1, CYP27B1 and CYP24A1, as 
well as VDR in response to vitaD3. It was also demonstrated 
that vitaD3 influenced the expression of osteogenic mRNA 
proColI, OC and OP in the same manner as 1,25OH
2
D3.
In addition to the effects of vitamin D metabolites on 
OPC1, vitamin D in combination with common osteogenic 
factors was investigated. It was demonstrated that in com-
bination with these osteogenic factors, matrix maturation 
and mineralization were significantly increased. However, 
there were differential results in bone maturation associ-
ated with ALP activity seen in cultures treated with BMP+. 
ALP expression is associated with bone cell phenotype, and 
in heavily mineralized cultures, cellular levels of ALP de-
cline [32]. OPC1 cultured in BMP+ with or without vitamin 
D metabolites demonstrated an increase in mineralization, 
and consequently with the mRNA expression of OC and OP, 
proteins that are known to increase with the accumulation 
of mineralization, compared to the BM- and BM+ groups. 
These results indicate that rhBMP-2 had a major influence 
on OPC1 bone mineralization, that may exceed the influ-
ence of vitamin D. A major limitation to this result, was that 
BMP+ cultures were so heavily mineralized that by day 17 
of culture time, the monolayer began to detach from the cul-
ture vessel.
It has been previously demonstrated that using dex, 
BMP-2 and 1,25OH
2
D3 tend to enhance a more differenti-
ated osteoblast phenotype [33]. However in our study, OP 
and OC mRNA expression in groups treated with vitaD3 or 
1,25OH
2
D3 and BMP+ was slightly lower than the BMP+ 
control, but higher than the osteogenic medium containing 
vitamin D metabolites and no BMP (BM+). This may be be-
cause we used a higher dose of 1,25OH2D3, which would 
also explain the very significant increase in catabolic enzyme 
mRNA expression of CYP24A1 seen in the second week of 
culture. In addition, it could be postulated that as a regulator 
of ECM mineralization, vitamin D dampened the effects of 
BMP. Many in vitro vitamin D studies investigating the anti-
proliferative and pro-differentiative effects of vitamin D are 
short-term and use a supra-physiological dose; however, for 
long-term cultures using vitamin D as an osteognenic factor, 
it may be beneficial to use a dose that more closely resembles 
the phsyiological dose. 
It has been long recognized that long-term or exces-
sive use of glucocorticoids (gC), whether from endogenous 
hypersecretion or iatrogenically, manifests adverse skeletal 
effects such as osteoporosis [34]. In human subjects receiv-
ing long-term gC treatment, bone loss is associated with 
the decrease in overall bone formation rate and in the mean 
thickness of the walls on newly synthesized trabecular bone, 
a pattern consistent with the decrease in number and/or ac-
tivity of osteoblasts rather than the increase in number and/
or activity of osteoblasts [34]. Paradoxically, several studies 
have demonstrated that treating cells derived from human 
bone with gCs promotes osteogenic differentiation, and has 
been proposed as a standard supplement for the ex vivo ex-
pansion of cells with osteogenic potential for use in tissue 
reconstruction and repair [34]. Dexamethasone is a GC that 
is commonly used as an inducer of bone marrow stromal cell 
differentiation, which reliably stimulates the development of 
many, but not all, phenotypic features of human osteoblasts 
[33]. However, GCs have deleterious effects in vivo, result-
ing in inhibition of osteoblast function. BMP-2 is another 
inducer of osteoblast differentiation, and is essential for 
postnatal bone formation. BMP-2 has been used to induce 
osteoblast differentiation in vitro in many human and animal 
models, and is believed to provide a more physiologic stimu-
lus than dexamethasone; however, it appears to enhance a 
more mature osteoblast characteristic [33].
Overall, this work provided baseline two-dimensional 
culture data characterizing the interaction between vitamin 
D metabolites and an osteoprecursor cell line. Ongoing ef-
forts are expanding this approach into a tissue engineered 
model created with three-dimensional culture and custom 
biomaterial scaffolds including the application of mechanical 
stimulation through access to a novel bioreactor [2]. In addi-
tion, the combined influence of vitamin D and biomechanics 
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on isolated single cells within an optofluidic environment is 
concurrently being investigated. This active research theme 
addresses multiscale mechanotransduction through novel 
bioengineering approaches.
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